Psilocybin Therapy for Advanced Cancer-related Psychiatric Distress
Psilocybin Therapy for Advanced Cancer-related Psychiatric Distress
批准号:
10659059
负责人:
STACY M FISCHER
金额:
$65.16万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-04 至 2027-06-30
关键词:
AcuteAddressAdjustment DisordersAdvanced Malignant NeoplasmAdverse effectsAffectAntidepressive AgentsAnxietyAnxiety DisordersAttentionBehaviorBehavior TherapyCancer PatientCessation of lifeClinicalClinical ResearchCognitionCognitiveDataDistressDoseDouble-Blind MethodEffectivenessEmotionalEnsureEnvironmentEvidence based interventionFeeling hopelessFoundationsGoalsHallucinogensHealthHourHumanIntegrative TherapyInterventionLifeLong-Term DepressionLong-Term EffectsMajor Depressive DisorderMalignant NeoplasmsManualsMeasuresMental DepressionMental HealthMental disordersMindMoodsOutcomeOutcome StudyPainParticipantPatient CarePatient Self-ReportPatientsPersonal SatisfactionPersonality TraitsPersonsPharmaceutical PreparationsPhysiologicalPlacebo ControlPlacebosPreparationPrevalencePsilocybinPsychotherapyPublic HealthQuality of lifeRandomizedRandomized, Controlled TrialsRelapseResearchSEER ProgramSafetySamplingScienceSiteSpiritualitySurvival RateTestingTherapeuticTherapeutic UsesTimeTreatment EfficacyTreatment ProtocolsTryptaminesWorkcancer carecancer diagnosiscancer survivalcancer therapyclinical careclinically significantcommon treatmentcompleted suicidedeath anxietydesigndisabilitydysphoriaeffective therapyefficacy evaluationemotional distressexperienceflexibilityfollow-upimprovedinnovationlife-limiting cancermedication compliancemedication nonadherencemental statemortalitynovel therapeutic interventionopen labelpeacepharmacologicplacebo grouppsychiatric comorbiditypsychologicpsychosocialresponsesuccesstrait
中文摘要
项目摘要/摘要
据估计,30%-40%的癌症患者经历了临床上明显的焦虑和抑郁。背负着
精神困扰引起的痛苦对生活质量(QOL)、药物治疗有深远的负面影响
坚持治疗,增加完全自杀率,甚至降低癌症存活率。大致
25%的晚期或晚期癌症患者经历了严重的生存苦恼
以士气低落、绝望、缺乏目的或意义、丧失尊严和匆忙为特征的
对死亡的渴望。药物治疗和社会心理治疗通常用于治疗抑郁、焦虑
以及癌症患者的生存苦恼,但它们的效果有限且喜忧参半。裸盖菇素是一种
迷幻色胺在人体实验室和临床研究中具有良好的生理-心理安全性,
产生非常显著的有意义的体验,通常被描述为精神/神秘的精神状态,
与认知、情感、行为和精神方面持续(几个月到几年)的积极变化有关。
基于大量的初步数据,裸盖菇素辅助治疗已经证明了安全性和
改善癌症相关抑郁和焦虑的初步疗效(效应大小=0.82-1.69),以及生存期
在改善生活质量的同时,参与者在初步试验中发现,这种体验既有
可接受的,非常有意义的,精神上的。在前期工作的坚实基础上,我们
建议进行两点、主动安慰剂对照、双盲、平行设计、随机对照
单次大剂量裸盖菇素辅助治疗与活性安慰剂(极小剂量裸盖菇素)对比试验200例
患有晚期癌症和基线精神痛苦的参与者。所有参赛者都将接受准备,
作为裸盖菇素组和活性安慰剂组的一部分,主动剂量和综合治疗会话。我们
建议进行以下目标:1)评估裸盖菇素对精神疾病的短期和长期影响
健康结局(如焦虑、抑郁、生存苦恼):2)评估裸盖菇素对生活质量的影响;
以及3)评价裸盖菇素诱导的心理改变机制的贡献(神秘
经验、人格特征开放性、认知灵活性)对急性和长期心理健康结果的影响
(抑郁、焦虑、生存苦恼)。我们将收集基线措施并在1处跟进结果
天、1周、8周、12周和24周(6个月)。这项拟议的研究将影响
通过测试一种创新的、以证据为基础的干预措施来改善抑郁症,
焦虑、生存苦恼和生活质量。这项研究意义重大,因为它解决了重要的心理问题
限制生命的癌症患者的痛苦的健康领域。这项研究具有创新性,可能是第一次
影响生存苦恼的有效治疗。此外,这项研究将通过评估
这一有希望的新治疗干预的心理变化机制。
英文摘要
Project Summary/ Abstract
An estimated 30-40% of cancer patients experience clinically significant anxiety and depression. The burden of
suffering caused by psychiatric distress has profound negative impacts on quality of life (QOL), medication
adherence, increased rates of completed suicide, and even decreased cancer survival rates. Approximately
25% of cancer patients with advanced or terminal cancer experience clinically significant existential distress
characterized by demoralization, hopelessness, absence of purpose or meaning, loss of dignity, and hastened
desire for death. Pharmacologic and psychosocial treatments are commonly used to treat depression, anxiety
and existential distress in cancer patients, but their effectiveness is limited and mixed. Psilocybin is a
psychedelic tryptamine with a good physiologic-psychological safety profile in human lab and clinical research,
producing highly salient meaningful experiences, often described as spiritual/mystical states of mind,
associated with enduring (months to years) positive changes in cognition, affect, behavior, and spirituality.
Based on extensive preliminary data, psilocybin-assisted therapy has demonstrated both safety and
preliminary efficacy to improve cancer-related depression and anxiety (effect size = 0.82-1.69), and existential
distress while improving quality of life, Participants in preliminary trials found the experience to be both
acceptable and highly meaningful and spiritual. Building on this strong foundation of preliminary work, we
propose to conduct a two-site, active placebo-controlled, double-blind, parallel design, randomized controlled
trial of single high dose psilocybin-assisted therapy versus active placebo (very low dose psilocybin) for 200
participants with advanced cancer and baseline psychiatric distress. All participants will receive preparatory,
active dosing, and integrative therapy sessions as part of the psilocybin and active placebo groups. We
propose to conduct the following aims: 1) To assess the short- and long-term effects of psilocybin on mental
health (e.g. anxiety, depression, existential distress) outcomes; 2) To assess the effects of psilocybin on QOL;
and 3) To evaluate the contribution of psilocybin-induced psychological change mechanisms (mystical
experience, personality trait openness, cognitive flexibility) on acute and long-term mental health outcomes
(depression, anxiety, existential distress). We will collect baseline measures and follow up of outcomes at 1
day, 1 week, 8 weeks, 12 weeks, and 24 weeks (6 months). The proposed study will impact clinical care for
persons with advanced cancer by testing an innovative, evidence-based intervention to improve depression,
anxiety, existential distress, and quality of life. The study is significant because it addresses important mental
health domains of suffering in patients with life-limiting cancer. The study is innovative as the potentially first
effective therapy to impact existential distress. Furthermore, this study will further the science by evaluating the
psychological change mechanisms for this promising new therapeutic intervention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Psilocybin Therapy for Advanced Cancer-related Psychiatric Distress
-
批准号:10534022
-
项目类别:
-
资助金额:$68.16万
-
财政年份:2022
-
负责人:STACY M FISCHER
-
依托单位:
Decision trajectories of patients at the end of life: An epidemiological exploration of MAID and the impact on caregivers and clinicians
-
批准号:10689820
-
项目类别:
-
资助金额:$62.57万
-
财政年份:2022
-
负责人:STACY M FISCHER
-
依托单位:
Decision trajectories of patients at the end of life: An epidemiological exploration of MAID and the impact on caregivers and clinicians
-
批准号:10539641
-
项目类别:
-
资助金额:$73.24万
-
财政年份:2022
-
负责人:STACY M FISCHER
-
依托单位:
Multidisciplinary Research Training in Palliative Care
-
批准号:10171736
-
项目类别:
-
资助金额:$34.06万
-
财政年份:2014
-
负责人:STACY M FISCHER
-
依托单位:
Multidisciplinary Research Training in Palliative Care
-
批准号:10426089
-
项目类别:
-
资助金额:$30.59万
-
财政年份:2014
-
负责人:STACY M FISCHER
-
依托单位:
Multidisciplinary Research Training in Palliative Care
-
批准号:10633133
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2014
-
负责人:STACY M FISCHER
-
依托单位:
Improving Care at the End of Life for Latinos:A Cultural Navigator Intervention
-
批准号:7475060
-
项目类别:
-
资助金额:$18.07万
-
财政年份:2006
-
负责人:STACY M FISCHER
-
依托单位:
Improving Care at the End of Life for Latinos:A Cultural Navigator Intervention
-
批准号:7879935
-
项目类别:
-
资助金额:$18.14万
-
财政年份:2006
-
负责人:STACY M FISCHER
-
依托单位:
Improving Care at the End of Life for Latinos:A Cultural Navigator Intervention
-
批准号:7152137
-
项目类别:
-
资助金额:$16.87万
-
财政年份:2006
-
负责人:STACY M FISCHER
-
依托单位:
海外基金